Cigna (CI)
NYSE:CI
Want to see CI full AI Analyst Report?
Top Page
Cigna
(NYSE:CI)
Select Model
Select Model
Rating:77Outperform
Price Target:
$339.00
▲(21.66% Upside)
Action:Reiterated
Date:05/14/26
Overall score reflects solid fundamentals at scale but tempered by margin compression and uneven recent cash flow growth, plus a favorable valuation (low P/E with a dividend) and supportive technical momentum. Earnings-call updates were constructive with raised 2026 EPS guidance, partially offset by near-term pressure in Pharmacy Benefit Services and cash flow timing.
Positive Factors
Scale & diversified revenue base
Cigna’s very large, diversified revenue base across insurance and health services produces meaningful absolute earnings and free cash flow, supporting reinvestment, dividends and buybacks. Size and product diversity reduce single-product risk and support durable contract leverage versus peers.
Negative Factors
Multi-year margin compression
Declining gross and EBITDA margins constrain operating leverage and make earnings more sensitive to medical cost trends and pricing dynamics. Sustained margin erosion could limit capital returns and raises the bar for future efficiency or product mix improvements to restore profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & diversified revenue base
Cigna’s very large, diversified revenue base across insurance and health services produces meaningful absolute earnings and free cash flow, supporting reinvestment, dividends and buybacks. Size and product diversity reduce single-product risk and support durable contract leverage versus peers.
Read all positive factors
Cigna Key Performance Indicators (KPIs)
Any
External Customers Revenue by Type
Shows revenue generated from different types of external customers, highlighting which customer segments are most lucrative and where there may be opportunities for growth or diversification.
Shows revenue generated from different types of external customers, highlighting which customer segments are most lucrative and where there may be opportunities for growth or diversification.
Data provided by:
The Fly
The FlyCigna (CI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.84B
Dividend Yield2.21%
Average Volume (3M)1.62M
Price to Earnings (P/E)10.6
Beta (1Y)0.27
Revenue Growth9.30%
EPS Growth30.22%
CountryUS
Employees71,295
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Plans
Share Statistics
EPS (TTM)23.72
Shares Outstanding264,532,400
10 Day Avg. Volume1,867,773
30 Day Avg. Volume1,616,753
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.75
Price to Sales (P/S)0.27
P/FCF Ratio8.73
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda8.28
Forecast
1Y Price Target
$335.46Price Target Upside20.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)30.44
Revenue Forecast (FY)$284.57B
Cigna Business Overview & Revenue Model
Company Description
The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and managem...
How the Company Makes Money
Cigna primarily makes money from (1) providing health insurance/benefits and (2) selling health services—especially pharmacy-related services—through Evernorth.
1) Health insurance / benefits (Cigna Healthcare):
- Premium revenue: Cigna collects ...
Cigna Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: consolidated revenue and EPS growth, a raised full-year EPS outlook, robust specialty and Cigna Healthcare performance, and meaningful innovation (rebate-free pharmacy model and AI-enabled savings). Primary headwinds centered on near-term PBS earnings pressure (28% decline) due to renewals and transition investments, a material special-items charge ($322M after-tax), and portfolio exits/strategic reviews that reduce near-term scope. Management presented these challenges as deliberate and manageable trade-offs to sharpen focus and accelerate long-term value creation.Positive Updates
Strong Consolidated Results and Raised Guidance
Total revenues of $68.5 billion and adjusted EPS of $7.79 in Q1 2026 (16% year-over-year EPS growth). Company raised full-year 2026 adjusted EPS outlook to at least $30.35.
Negative Updates
Pharmacy Benefit Services (PBS) Earnings Decline
PBS pretax adjusted earnings decreased 28% year-over-year to $394 million (a decline of about $150 million in the quarter), driven by large client renewals/extensions and investments to transition to the new rebate-free Signature model.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Consolidated Results and Raised Guidance
Total revenues of $68.5 billion and adjusted EPS of $7.79 in Q1 2026 (16% year-over-year EPS growth). Company raised full-year 2026 adjusted EPS outlook to at least $30.35.
Read all positive updates
Company Guidance
Cigna raised full‑year 2026 adjusted EPS guidance to at least $30.35 after a strong Q1 that delivered total revenues of $68.5B and adjusted EPS of $7.79 (16% YoY); Q1 included after‑tax special charges of $322M ($1.22/sh). Evernorth Q1 revenues rose 9% to $58.4B with pretax adjusted earnings up 2% to $1.5B (Specialty & Care Services pretax adj. earnings +20% to $1.1B; Pharmacy Benefit Services pretax adj. earnings -28% to $394M, ≈$150M decline YoY) and Evernorth full‑year adjusted income from operations is expected to be at least $6.9B (Q2 pretax seasonality similar to historical patterns). Cigna Healthcare posted Q1 revenues of $11.5B and pretax adjusted earnings of $1.5B, with a Q1 medical care ratio of 79.8% and full‑year pretax adjusted earnings guidance of at least $4.525B (first half slightly above 60% of the full year; full‑year MCR guidance unchanged at 83.7%–84.7%; Q2 MCR expected slightly above the high end). Capital and cash metrics: Q1 operating cash flow was $1.1B, debt‑to‑capital was 42.3% (improved 70 bps vs. year‑end 2025) and the company expects most 2026 operating cash flow in H2 and a lower debt‑to‑capital by year‑end; longer‑term PBM transition targets include at least 50% of PBS members on the new rebate‑free Signature model by year‑end 2028.Cigna Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
72
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.94B | 274.95B | 247.12B | 195.26B | 180.52B | 174.07B |
| Gross Profit | 25.85B | 25.99B | 25.96B | 25.18B | 23.50B | 22.95B |
| EBITDA | 11.93B | 11.61B | 11.45B | 10.85B | 10.44B | 9.96B |
| Net Income | 6.29B | 5.96B | 3.43B | 5.16B | 6.70B | 5.37B |
Balance Sheet | ||||||
| Total Assets | 153.27B | 157.92B | 155.88B | 152.76B | 143.88B | 154.89B |
| Cash, Cash Equivalents and Short-Term Investments | 7.85B | 7.68B | 8.21B | 8.75B | 6.83B | 6.00B |
| Total Debt | 30.90B | 31.46B | 31.97B | 30.93B | 31.55B | 34.27B |
| Total Liabilities | 110.82B | 116.05B | 114.64B | 106.41B | 98.98B | 107.70B |
| Stockholders Equity | 42.21B | 41.71B | 41.03B | 46.22B | 44.87B | 47.11B |
Cash Flow | ||||||
| Free Cash Flow | 7.66B | 8.39B | 8.96B | 10.24B | 7.36B | 6.04B |
| Operating Cash Flow | 8.81B | 9.60B | 10.36B | 11.81B | 8.66B | 7.19B |
| Investing Cash Flow | -6.24B | -4.41B | -2.10B | -5.17B | 3.10B | -3.61B |
| Financing Cash Flow | -3.88B | -6.42B | -7.65B | -4.29B | -11.24B | -8.21B |
Cigna Technical Analysis
Positive
278.64
Price Trends
275.96
Positive
277.45
Positive
279.95
Positive
Market Momentum
4.08
Negative
56.04
Neutral
41.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CI, the sentiment is Positive. The current price of 278.64 is below the 20-day moving average (MA) of 285.94, above the 50-day MA of 275.96, and below the 200-day MA of 279.95, indicating a bullish trend. The MACD of 4.08 indicates Negative momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 41.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CI.
Cigna Risk Analysis
Cigna disclosed 27 risk factors in its most recent earnings report. Cigna reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cigna Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $75.84B | 10.59 | 15.16% | 2.21% | 9.30% | 30.22% | |
75 Outperform | $85.58B | 9.15 | 11.95% | 1.99% | 9.44% | -8.53% | |
74 Outperform | $355.20B | 9.80 | 12.40% | 2.69% | 9.67% | -44.84% | |
70 Outperform | $36.74B | 4.40 | 6.19% | 1.38% | 14.08% | -33.82% | |
69 Neutral | $122.48B | 7.77 | 3.87% | 3.41% | 7.68% | -45.09% | |
63 Neutral | $28.75B | 2.61 | -28.72% | ― | 17.02% | -294.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CI
Cigna
283.10
-27.42
-8.83%
CNC
Centene
58.28
-2.46
-4.05%
CVS
CVS Health
93.28
33.36
55.68%
HUM
Humana
304.10
62.15
25.69%
UNH
UnitedHealth
383.30
88.63
30.08%
ELV
Elevance Health
396.21
4.45
1.14%
Cigna Corporate Events
Business Operations and StrategyFinancial Disclosures
Cigna Reaffirms 2026 Outlook and Profitability Targets
Positive
May 13, 2026
The Cigna Group said it will reaffirm its previously issued 2026 outlook as executives meet with investors and analysts in the coming weeks. The company continues to project full-year 2026 consolidated adjusted income from operations of at least $...
Executive/Board ChangesShareholder Meetings
Cigna Shareholders Back Board, Pay Plan at Meeting
Positive
Apr 27, 2026
At The Cigna Group’s Annual Meeting of Shareholders held on April 22, 2026, approximately 90% of outstanding shares were represented, and shareholders elected all 12 director nominees to one-year terms, signaling continued support for the ex...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Cigna Announces CEO Succession and Leadership Transition Plan
Positive
Mar 3, 2026
On February 25, 2026, The Cigna Group’s board approved a leadership transition under which long-serving chief executive David M. Cordani will retire as CEO on July 1, 2026 and become executive chair, while president and COO Brian C. Evanko, ...
Business Operations and StrategyFinancial Disclosures
Cigna Reaffirms 2026 Adjusted Earnings Outlook to Investors
Positive
Feb 27, 2026
The Cigna Group said it will use upcoming meetings with investors and analysts to reaffirm its previously stated outlook for full-year 2026 consolidated adjusted income from operations of at least $30.25 per share. Management emphasized that this ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.